Applied Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Applied Therapeutics wird ein Gewinn- und Umsatzwachstum von 42.1% bzw. 59% pro Jahr prognostiziert, während der Gewinn pro Aktie um 59.3% pro Jahr wachsen soll.

Wichtige Informationen

42.1%

Wachstumsrate der Gewinne

59.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	59.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Nov 15

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Sep 18

Applied Therapeutics: Pushing Towards FDA Approval

Sep 04

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Aug 01

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

May 28

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24

Applied Therapeutics EPS misses by $0.21

Nov 12

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:APLT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	155	-73	N/A	N/A	3
12/31/2025	57	-88	N/A	N/A	4
12/31/2024	1	-180	N/A	N/A	3
9/30/2024	0	-187	-82	-82	N/A
6/30/2024	0	-161	-73	-73	N/A
3/31/2024	0	-194	-67	-67	N/A
12/31/2023	10	-120	-55	-55	N/A
9/30/2023	11	-97	-54	-54	N/A
6/30/2023	11	-73	-59	-59	N/A
3/31/2023	11	-70	-61	-61	N/A
12/31/2022	N/A	-83	-78	-78	N/A
9/30/2022	N/A	-95	-89	-89	N/A
6/30/2022	N/A	-105	-85	-85	N/A
3/31/2022	N/A	-105	-93	-93	N/A
12/31/2021	N/A	-106	-91	-91	N/A
9/30/2021	N/A	-102	-87	-87	N/A
6/30/2021	N/A	-104	-92	-92	N/A
3/31/2021	N/A	-106	-82	-82	N/A
12/31/2020	N/A	-94	-78	-78	N/A
9/30/2020	N/A	-88	-68	-68	N/A
6/30/2020	N/A	-69	-55	-55	N/A
3/31/2020	N/A	-49	-48	-48	N/A
12/31/2019	N/A	-46	-36	-36	N/A
9/30/2019	N/A	-35	-30	-30	N/A
6/30/2019	N/A	-28	-24	-24	N/A
3/31/2019	N/A	-23	-17	-17	N/A
12/31/2018	N/A	-17	-11	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: APLT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: APLT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: APLT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: APLTDie Einnahmen des Unternehmens (59% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: APLTDie Einnahmen des Unternehmens (59% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von APLT in 3 Jahren voraussichtlich hoch sein wird

Applied Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 38%

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Consensus EPS estimates fall by 36%

Consensus EPS estimates fall by 13%

Consensus revenue estimates fall by 27%

Recent updates

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

Applied Therapeutics: Pushing Towards FDA Approval

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Consensus revenue estimates decrease by 38%

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

Chair of the Board of Directors recently sold US$1.7m worth of stock

New major risk - Revenue and earnings growth

Applied Therapeutics, Inc. announced that it expects to receive $99.997998 million in funding from a group of investors

Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Independent Director recently bought US$65k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Consensus EPS estimates fall by 36%

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

New major risk - Shareholder dilution

Consensus EPS estimates fall by 13%

Consensus revenue estimates fall by 27%

New major risk - Financial position

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Consensus revenue estimates decrease by 21%

Consensus revenue estimates increase by 89%

Consensus revenue estimates increase by 1,731%

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Price target increased by 27% to US$15.00

Insufficient new directors

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

Applied Therapeutics, Inc. Announces Positive Data Trend in AT-007 Action-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

Price target increased to US$16.50

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell 2000 Growth Index

Applied Therapeutics Receives Orphan Medicinal Product Designation from the Ema for AT-007 for Treatment of Galactosemia

Insufficient new directors

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Price target decreased to US$12.10

Applied Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$13.63

Price target decreased to US$28.80

Applied Therapeutics, Inc. Announces Executive Changes

Applied Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Price target increased to US$39.20

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

Applied Therapeutics, Inc Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

Price target decreased to US$34.40

Price target increased to US$49.40

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Chair of the Board of Directors recently bought US$145k worth of stock

Chief Medical Officer notifies of intention to sell stock

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Chief Medical Officer exercised options and sold US$714k worth of stock

Chief Medical Officer exercised options and sold US$97k worth of stock

Price target decreased to US$44.50

Applied Therapeutics Grants Fast Track Designation by FDA for AT-007 for Galactosemia

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

CFO & Head of Business Development recently sold US$108k worth of stock

Chief Commercial Officer recently sold US$53k worth of stock

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2025